AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05367089
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months.
Trial: NCT05102162
Drug: Cefepime, Meropenem, or Piperacillin/Tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
Trial: NCT00043797
Drug: Lidorestat (IDD 676)
RxNorm normalized name: Lidostat
DrugBank: Lidorestat (DB07063)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001062
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04527393
Drug: Individualized oral morphine
RxNorm normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose.
Trial: NCT04527393
Drug: Conventional oral morphine
RxNorm normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose.
Trial: NCT05478356
Drug: low-dose atropine eye drops
RxNorm normalized name: ethinyl estradiol
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low-dose atropine eye drops
Trial: NCT06541509
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed.
Trial: NCT06362707
Drug: Fasudil
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
Trial: NCT04947085
Drug: Ketamine via Intravenous
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine administration in sub-dissociative doses
Trial: NCT04947085
Drug: Ketamine via BAN
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine administered via Breath-Actuated Nebulizer (BAN)
Trial: NCT04836832
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04836832
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04869475
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is a single-arm study with all patients receiving arsenci trioxide.
Trial: NCT06348290
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06348290
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT06348290
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06348290
Drug: dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06348290
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05224167
Drug: Hydroxyzine
RxNorm normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
Trial: NCT06096909
Drug: Tafolecimab
RxNorm normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
Trial: NCT05208840
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
Trial: NCT04998669
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle.
Trial: NCT06455046
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1/CTLA-4 bispecific antibody
Trial: NCT06455046
Drug: Recombinant Human Adenovirus 5 Injection
RxNorm normalized name: Human adenovirus b serotype 7
DrugBank: Human adenovirus b serotype 7 (DB14410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Adenovirus 5 Injection
Trial: NCT05657873
Drug: Platinum based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
Trial: NCT01076439
Drug: Fluticasone Furoate Nasal Spray
RxNorm normalized name: fluticasone furoate Metered Dose Nasal Spray
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate Nasal Spray: 110mcg QD
Trial: NCT01076439
Drug: Olopatadine Nasal Spray
RxNorm normalized name: olopatadine Metered Dose Nasal Spray
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine Nasal Spray: 2660mcg BID
Trial: NCT04448028
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
Trial: NCT04998669
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.
Trial: NCT06193044
Drug: Amlodipine/Valsartan
RxNorm normalized name: AMLODIPINE/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Amlodipine 10 mg \&valsartan 160 mg
Trial: NCT06193044
Drug: Amlodipine 10 mg &valsartan 160 mg (Exforge)
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Amlodipine 10 mg \&valsartan 160 mg
Trial: NCT06357676
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06145399
Drug: 18F-FDHT
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
Trial: NCT05751018
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
Trial: NCT04660097
Drug: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
Trial: NCT06319950
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib, 160mg po qd
Trial: NCT06319950
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib，80mg po qd
Trial: NCT04764669
Drug: E2027
RxNorm normalized name: Elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hypromellose capsules.
Trial: NCT05519540
Drug: Xevinapant (Debio 1143)
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
Trial: NCT05450900
Drug: Choriogonadotropin Alpha
RxNorm normalized name: choriogonadotropin alpha
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug, active
Trial: NCT04726969
Drug: Moxidectin 2 mg Oral Tablet
RxNorm normalized name: moxidectin 2 mg ORAL TABLET
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 2 mg moxidectin
Trial: NCT04726969
Drug: Albendazole 400 mg Oral Tablet
RxNorm normalized name: albendazole 400 MG Oral Tablet
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 400 mg albendazole
Trial: NCT04726969
Drug: Ivermectin 3 mg Oral Tablet
RxNorm normalized name: ivermectin 3 MG Oral Tablet
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 3 mg ivermectin
Trial: NCT02614352
Drug: Atorvastatin + Candesartan
RxNorm normalized name: atorvastatin, amlodipine and candesartan
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05182840
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets
Trial: NCT05182840
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin
Trial: NCT05182840
Drug: Placebo to empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to empagliflozin
Trial: NCT05742607
Drug: IPH5201 + durvalumab + standard chemotherapy
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.
Trial: NCT05366868
Drug: Imeglimin
RxNorm normalized name: imeglimin
DrugBank: Imeglimin (DB12509)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
Trial: NCT05366868
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
Trial: NCT05366868
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
Trial: NCT04928625
Drug: SHR-A1904
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1904
Trial: NCT05214339
Drug: Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
Trial: NCT04708236
Drug: ORTD-1 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Trial: NCT04708236
Drug: ORTD-1 high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Trial: NCT04744090
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended.
Trial: NCT04684238
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for Injection/Infusion
Trial: NCT04684238
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
Trial: NCT04901689
Drug: Leronlimab
RxNorm normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab 700 mg
Trial: NCT06287177
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Injection
Trial: NCT06326723
Drug: Daridorexant
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.).
Trial: NCT05816499
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV, 10mg/kg Q3W
Trial: NCT05816499
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral，6mg/8mg/10mg qd 2W/3W
Trial: NCT05816499
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV, 60-75mg/m2 Q3W
Trial: NCT05439005
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine+Lidocaine
Trial: NCT05040113
Drug: CBP-307
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP-307 capsules oral administration
Trial: NCT04909918
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
Trial: NCT04909918
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
Trial: NCT00002069
Drug: Ditiocarb sodium
RxNorm normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06254131
Drug: Ondansetron lozenge (Ondalenz ©)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
Trial: NCT06254131
Drug: Ondansetron IV
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
Trial: NCT05960721
Drug: Rivaroxaban 15mg
RxNorm normalized name: RIVAROXABAN 15MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: QD
Trial: NCT05960721
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QD
Trial: NCT05960721
Drug: Clopidogrel 75mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: QD
Trial: NCT05960721
Drug: Rivaroxaban 10mg
RxNorm normalized name: RIVAROXABAN 10MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: QD
Trial: NCT05960721
Drug: Rivaroxaban 2.5mg
RxNorm normalized name: RIVAROXABAN 2.5MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: B.I.D
Trial: NCT04211675
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.